Healthcare provider profile · identity verified

John S Smoots, MD

Internal Medicine · TACOMA, WA · NPI 1285645945

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	367	107
Rosuvastatin Calcium	Rosuvastatin Calcium	365	131
Atorvastatin Calcium	Atorvastatin Calcium	331	121
Metoprolol Succinate	Metoprolol Succinate	270	97
Irbesartan	Irbesartan	230	84
Amlodipine Besylate	Amlodipine Besylate	198	72
Ozempic	Semaglutide	154	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	143	33
Eliquis	Apixaban	139	32
Gabapentin	Gabapentin	135	50
Omeprazole	Omeprazole	127	57
Famotidine	Famotidine	119	46
Jardiance	Empagliflozin	119	36
Montelukast Sodium	Montelukast Sodium	116	43
Duloxetine Hcl	Duloxetine Hcl	108	32
Finasteride	Finasteride	106	35
Trazodone Hcl	Trazodone Hcl	96	35
Metformin Hcl Er	Metformin Hcl	95	43
Escitalopram Oxalate	Escitalopram Oxalate	94	38
Pantoprazole Sodium	Pantoprazole Sodium	92	33
Albuterol Sulfate Hfa	Albuterol Sulfate	87	43
Doxepin Hcl	Doxepin Hcl	84	23
Allopurinol	Allopurinol	82	27
Tamsulosin Hcl	Tamsulosin Hcl	80	27
Spironolactone	Spironolactone	76	26
Lisinopril	Lisinopril	73	29
Tramadol Hcl	Tramadol Hcl	73	17
Cephalexin	Cephalexin	72	49
Fluticasone Propionate	Fluticasone Propionate	70	32
Propranolol Hcl Er	Propranolol Hcl	70	25
Azithromycin	Azithromycin	67	51
Prednisone	Prednisone	64	28
Metformin Hcl	Metformin Hcl	62	25
Furosemide	Furosemide	52	19
Amitriptyline Hcl	Amitriptyline Hcl	50	19
Triamcinolone Acetonide	Triamcinolone Acetonide	49	32
Clopidogrel	Clopidogrel Bisulfate	46	22
Metoprolol Tartrate	Metoprolol Tartrate	46	17
Paxlovid	Nirmatrelvir/Ritonavir	46	46
Esomeprazole Magnesium	Esomeprazole Magnesium	44	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	43	14
Colchicine	Colchicine	42	13
Liothyronine Sodium	Liothyronine Sodium	42	14
Doxycycline Hyclate	Doxycycline Hyclate	41	28
Ketoconazole	Ketoconazole	40	18
Topiramate	Topiramate	40	16
Zolpidem Tartrate	Zolpidem Tartrate	40	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	39	suppressed
Bupropion Xl	Bupropion Hcl	38	16
Mounjaro	Tirzepatide	37	suppressed
Nitroglycerin	Nitroglycerin	37	25
Ondansetron Odt	Ondansetron	37	suppressed
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Mupirocin	Mupirocin	34	20
Losartan Potassium	Losartan Potassium	33	16
Terazosin Hcl	Terazosin Hcl	33	15
Xarelto	Rivaroxaban	32	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	24
Creon	Lipase/Protease/Amylase	31	suppressed
Ipratropium Bromide	Ipratropium Bromide	31	12
Atenolol	Atenolol	29	suppressed
Latanoprost	Latanoprost	27	suppressed
Alprazolam	Alprazolam	25	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	12
Methocarbamol	Methocarbamol	25	13
Potassium Chloride	Potassium Chloride	25	13
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Testosterone Cypionate	Testosterone Cypionate	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Valacyclovir	Valacyclovir Hcl	23	15
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Simvastatin	Simvastatin	22	suppressed
Sucralfate	Sucralfate	22	12
Estradiol	Estradiol	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Ciclopirox	Ciclopirox	20	12
Nystatin	Nystatin	20	12
Acetaminophen-Codeine	Acetaminophen With Codeine	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	18	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Torsemide	Torsemide	18	suppressed
Fluconazole	Fluconazole	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Rybelsus	Semaglutide	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Digoxin	Digoxin	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Verapamil Er Pm	Verapamil Hcl	14	suppressed
Diazepam	Diazepam	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Balsalazide Disodium	Balsalazide Disodium	11	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Colestipol Hcl	Colestipol Hcl	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Glipizide	Glipizide	11	suppressed
Linzess	Linaclotide	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error